Core Viewpoint - The stock of Baiaosaitu-B (02315) surged over 11%, reaching a new historical high of 44 HKD, following the announcement of a collaboration agreement with Yushibo to advance the development of bispecific antibody-drug conjugates (BsADC) [1] Group 1: Company Developments - Baiaosaitu has entered into an option and licensing agreement with Yushibo, aimed at systematically evaluating the BsADC projects through a structured assessment mechanism [1] - The agreement grants Yushibo an option for global exclusive licensing of two BsADC projects from Baiaosaitu [1] - Baiaosaitu is entitled to receive an upfront payment for the option, and upon Yushibo exercising the option, Baiaosaitu will also receive subsequent payments including option exercise fees, development and regulatory milestone payments, commercialization milestone payments, and sales royalties [1]
港股异动 涨超11%再创新高 公司就偶联物项目与育世博达成进一步合作